UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------------------------|------------------------ ...

Advance every day together Investor Presentation March 7, 2022 Mission To develop and provide solutions that make life better for people living with diabetes Vision A life unlimited by diabetes 1 Forward-looking statements This presentation contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding Embecta Corp.'s ("embecta's") future prospects and performance, including, but not limited to, future revenues, margins, leverage targets, and capital dep ...

Becton, Dickinson and Company (NYSE:BDX) Q1 2022 Earnings Conference Call February 3, 2022 8:30 AM ET Company Participants Francesca DeMartino - SVP, IR Thomas Polen - President, CEO & Chairman Christopher DelOrefice - EVP & CFO Simon Campion - EVP & President, Interventional Segment Conference Call Participants Vijay Kumar - Evercore ISI Robert Marcus - JPMorgan Chase & Co. Matthew Mishan - KeyBanc Capital Markets Lawrence Biegelsen - Wells Fargo Securities Matthew Taylor - UBS Frederick Wise - Stifel, Nic ...

| --- | --- | |------------------------------------------------|-------------------------------------| | | | | | | | Q1 FY22 Earnings Presentation February 3, 2022 | | | | Advancing the world of health TM | Caution Concerning Forward-Looking Statements This presentation contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's future prospects and performance, including, but not limited to, future revenues, margins, and earnings per share, leve ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common stock, par value $1.00 BDX New York Stock Exchange Depositary Shares, each representing a 1/20th interest in a share of 6.00% Mandatory Convertible Preferred Stock, Series B BDXB New York Stock Exchange ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 001-4802 BECTON, DICKINSON AND COMPANY (Exact name of registrant as specified in its charter) New Jersey 22-0760120 (Sta ...

Becton, Dickinson and Company (NYSE:BDX) Q4 2021 Earnings Conference Call November 4, 2021 8:00 AM ET Company Participants Nadia Goncalves - SD, IR Tom Polen - Chairman, CEO & President Chris DelOrefice - EVP &CFO Alberto Mas - President, Medical Segment Simon Campion - President, Interventional Segment Dave Hickey - President, Life Sciences Segment Conference Call Participants Vijay Kumar - Evercore ISI Bob Hopkins - Bank of America Robbie Marcus - J.P. Morgan Matthew Mishan - KeyBanc Larry Biegelsen - Wel ...

Financial Data and Key Metrics Changes - Revenues totaled $4.9 billion, up 26.9% on a reported basis and 22% on a currency-neutral basis, exceeding expectations [14][61] - Adjusted EPS was $2.74, reflecting a 24.5% increase over the prior year [78] - Year-to-date cash flows from operations totaled $3.7 billion, an increase of 80% from the prior-year period [21] Business Line Data and Key Metrics Changes - BD Medical segment revenues totaled $2.4 billion, up 7.7% year-over-year [63] - Pharmaceutical Systems revenues increased by 12%, driven by demand for prefilled devices [65] - BD Life Sciences revenues reached $1.4 billion, up 43%, including $300 million from COVID diagnostic testing [65][66] - BD Interventional sales totaled nearly $1.1 billion, up nearly 35%, with surgery revenues increasing by 68% [69] Market Data and Key Metrics Changes - Base business revenues increased 17.6% excluding COVID diagnostic revenues [15][62] - Revenues from the Pharmaceutical Systems and Urology/Critical Care franchises were up 17% and 11% respectively compared to 2019 levels [18] - MDS revenues were up about 2% versus 2019 levels, reflecting ongoing impacts from COVID and China volume-based purchasing [19] Company Strategy and Development Direction - The company is focused on its BD 2025 strategy, emphasizing growth, simplification, and empowerment [29] - Investments are being made in new innovations to strengthen market leadership and drive growth in high-potential areas [30][31] - The company plans to spin off its Diabetes Care business into an independently traded company, expected in the first half of 2022 [50][56] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the recovery of the base business and expects strong mid-single-digit revenue growth for fiscal 2022 [57][86] - The company anticipates continued positive momentum in its base business, with a revised revenue growth expectation of approximately 14% [80] - Management acknowledged challenges from inflation and COVID-related impacts but remains optimistic about margin recovery [108][130] Other Important Information - The company repurchased $1 billion in stock, marking the first repurchase since 2017 [21] - The gross margin was reported at 51.5%, impacted by COVID-related expenses and manufacturing variances [71][72] - The company is actively working on the remediation of the BD Alaris pump, which remains a top priority [25][26] Q&A Session Summary Question: Can you explain the difference between 2019 margins and the new guidance for 2022? - Management indicated that the primary differences are due to the Alaris ship hold, China price cuts, and inflationary pressures [99][100] Question: When do inflationary costs abate? - Management expects inflationary pressures to ease, but it will take time to fully pass on cost increases to customers [108][109] Question: What is the timeline for getting back to pre-pandemic margins? - Management believes that margins could return to 2019 levels within the next couple of years as Alaris comes back and continuous improvements are realized [104][100] Question: What are the expectations for Q4 revenue guidance? - Management noted that Q4 comparisons are challenging due to a strong prior year and investments made this year will impact margins [119][120] Question: What is the outlook for the tax rate next year? - The tax rate is expected to be at the low end of the traditional guidance range of 14% to 16% [132]

| --- | --- | |------------------------------------------|-------| | | | | | | | | | | | | | | | | Creating value by fulfilling our purpose | | | Advancing the World of Health ™ | | | August 5, 2021 | | Caution Concerning Forward-Looking Statements This presentation contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's future prospects and performance, including, but not limited to, future revenues, margins, earnings per share, leverage tar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-4802 Becton, Dickinson and Company (Exact name of registrant as specified in its charter) New Jersey 22-0760120 (State or other j ...